^(131)I难治性分化型甲状腺癌的再分化治疗  

Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer

作　　者：程凌霄[1] 陈立波[1] 

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《中国癌症杂志》2016年第1期35-42,共8页China Oncology

基　　金：国家自然科学基金(81271609);上海市科技启明星(12QH1401600)

摘　　要：^(131)I难治性分化型甲状腺癌(radioiodine-refractory differentiated thyroid cancer,RR-DTC)是目前甲状腺癌临床治疗领域的一大难题。维甲酸类药物、过氧化物酶体增殖物激活受体激动剂、DNA甲基化酶抑制剂及组蛋白脱乙酰化酶抑制剂都曾被用于诱导RR-DTC再分化并与^(131)I联合治疗,但疗效并不显著。近年来,随着对RR-DTC分子机制认识的不断深入,靶向治疗等新的再分化治疗策略越来越多地被尝试用于治疗RRDTC。相比之下,分子靶向药物用于诱导RR-DTC重摄碘及介导^(131)I治疗效果较好,可能具有良好的应用前景。Clinical management of radioiodine-refractory differentiated thyroid cancer （RR-DTC） is extremely difficult. Re-differentiation compounds, such as retinoids, peroxisome proliferator-activated receptor （PPAR） agonists, DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been used in trials to increase iodine uptake in RR-DTC. However, data on these drugs failed to meet the initial high expectations. In recent years, targeted agents have been increasingly used in pre-clinical and clinical studies to induce re-differentiation and mediate 131I therapy, and the outcomes are encouraging.

关 键 词：甲状腺癌 再分化治疗 靶向药物 131I 

分 类 号：R736.1[医药卫生—肿瘤]